Abstracts tagged "remission and systemic lupus erythematosus (SLE)"

Abstract Number: 745 • 2018 ACR/ARHP Annual Meeting
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: A Multi-Center Cohort Study from China
Ziqian Wang¹, Jiuliang ZHAO², Yanhong Wang³, Mengtao Li⁴ and Xiaofeng Zeng⁵, ¹Peking Union Medical College Hospital, China, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ³Department of Epidemiology and Bio-statistics (YW), Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: a Multi-center Cohort Study from ChinaZiqian Wang1, Jiuliang Zhao1, Yanhong…
Abstract Number: 1684 • 2018 ACR/ARHP Annual Meeting
Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality
Manuel Ugarte-Gil^1,2, Rocío Gamboa-Cárdenas³, Mariela Medina-Chinchon³, Cristina Reategui-Sokolova³, Francisco Zevallos³, Claudia Elera-Fitzcarrald^3,4, Victor R. Pimentel-Quiroz³, Erika Noriega¹, Zoila Rodriguez-Bellido^3,5, Cesar A. Pastor-Asurza^3,5, Graciela S. Alarcón^6,7 and Risto Perich-Campos^3,5, ¹Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Rheumatology, Universidad Científica del Sur, Lima, Peru, ³Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Universidad Peruana Cayetano Heredia, Lima, Peru, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Achieving remission and low lupus disease activity state (LDAS) in systemic lupus erythematosus (SLE) patients improves their prognosis in terms of damage accrual. But,…
Abstract Number: 1691 • 2018 ACR/ARHP Annual Meeting
Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns
Francesca Dall'Ara¹, Laura Andreoli², Federica Migliorati³, Giuseppe Armentaro³, Micaela Fredi⁴, Micol Frassi⁵, Mara Taraborelli³, Franco Franceschini⁴, Stefano Calza⁶ and Angela Tincani³, ¹Department of Clinical and Experimental Sciences,Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, ⁴Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ⁵Spedali Civili of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, ⁶Unit of Biostatistics and Biomathematics & Unit of Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by a fluctuating course. To achieve sustained remission is the ultimate goal of maintenance treatment. However the definition…
Abstract Number: 1700 • 2018 ACR/ARHP Annual Meeting
Remission and Low Disease Activity State Prevent Hospitalizations and Emergency Room Visits in Systemic Lupus Erythematosus Patients
Cristina Reategui-Sokolova¹, Rocío Gamboa-Cárdenas¹, Mariela Medina-Chinchon¹, Francisco Zevallos¹, Claudia Elera-Fitzcarrald^1,2, Victor R. Pimentel-Quiroz¹, Mariano Cucho-Venegas¹, Zoila Rodriguez-Bellido¹, Cesar A. Pastor-Asurza^1,3, Risto Perich-Campos¹, Graciela S. Alarcón^4,5 and Manuel Ugarte-Gil^6,7, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁴Universidad Peruana Cayetano Heredia, Lima, Peru, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology, Universidad Científica del Sur, Lima, Peru, ⁷Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru
Background/Purpose: Although the survival rate of patients with Systemic Lupus Erythematosus (SLE) has improved over the years, patients are frequently hospitalized or evaluated in the…
Abstract Number: 2929 • 2018 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman¹ and Laurence S Magder², ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
Abstract Number: 1805 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Complete Remission in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in One Center
Jorge Romo-Tena¹, Diana Gómez-Martín¹, Roberto Reyna², Isaac Bartnicki-Navarrete³ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by disease flares, alternated with periods of clinical remission. In the past years, the “treat-to-target” strategy in SLE…
Abstract Number: 1779 • 2016 ACR/ARHP Annual Meeting
Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Manuel Ugarte-Gil^1,2, Daniel Wojdyla³, Guillermo J. Pons-Estel⁴, Luis J. Catoggio⁵, Cristina Drenkard⁶, Judith Sarano⁷, Guillermo Berbotto⁸, Eduardo Borba⁹, Emilia Sato¹⁰, Joao Carlos Brenol¹¹, Oscar Uribe¹², Luis Ramirez¹², Marlene Guibert-Toledano¹³, Loreto Massardo¹⁴, Mario Cardiel¹⁵, Luis H. Silveira¹⁶, Rosa Chacón-Díaz¹⁷, Graciela S. Alarcón¹⁸, Bernado Pons-Estel¹⁹ and GLADEL (Grupo LatinoAmericano de Estudio de Lupus), ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³GLADEL consultant, Rosario, Argentina, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁸Sanatorio Británico, Rosario, Argentina, ⁹Faculdade de Medicina, Hospital das Clínicas. Universidade de São Paulo, São Paulo, Brazil, ¹⁰Rheumatology Division. Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹¹Hospital das Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brazil, ¹²Hospital Universitario “San Vicente de Paul”, Universidad de Antioquia, Medellín, Colombia, ¹³Rheumatology, Centro de Investigaciones Médico Quirúrgicas, Habana, Ciudad Habana, Cuba, ¹⁴Departments of Immunology & Rheumatology, Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁵Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ¹⁶Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ¹⁷Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ¹⁸Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Sanatorio Parque, Rosario, Argentina
Background/Purpose: Recently, definitions of both Remission and LLDAS have been proposed which include disease activity status and medication intake [immunosuppressive (IS) drugs and corticosteroids]. The…
Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Kichul Ko¹, Alana B. Levine², Russell Griffin³, Olga Dvorkina⁴, Saira Sheikh⁵, Jinoos Yazdany⁶, Richard Furie⁷ and Cynthia Aranow⁸, ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ⁸Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
Abstract Number: 1566 • 2013 ACR/ARHP Annual Meeting
Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Eric F. Morand¹, Kate Franklyn¹, Chak S. Lau², Sandra V. Navarra³, Worawit Louthrenoo⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Singgih Wahono⁷, Shun-Le Chen⁸, Jinou Ou⁹, Alberta Y. Hoi¹ and Mandana Nikpour¹⁰, ¹Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³University of Santo Tomas Hospital, Manila, Philippines, ⁴Dept of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Bandung, Indonesia, ⁷Universitas Brawijaya, Malang, Indonesia, ⁸Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁹3rd Hospital of Sun Yat-san University, Guang Zhou, China, ¹⁰Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia
Background/Purpose: The definitions of low disease activity state (LDAS) and remission as desirable treatment goals in rheumatoid arthritis have been widely applied in research and…
Abstract Number: 679 • 2012 ACR/ARHP Annual Meeting
ZAP70+ B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis
Elisa Gremese, Barbara Tolusso, Laura Messuti, Marcin Nowik, Silvia Canestri, Luca Petricca, Maria Rita Gigante and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: To analyze differences in B cells subsets distribution in patients with renal systemic lupus erythematosus (SLE). To define possible cellular biomarkers of active nephritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].